Zhong Ji Longevity Science Group Limited (0767) AI Stock Analysis

• Market Cap: HK$202.22M
• Dividend Yield: N/A
• Average Volume (3M): 373.97K
• Price to Earnings (P/E): ―
• Beta (1Y): <0.01
• Revenue Growth: 156.72%
• EPS Growth: -2758.33%
• Country: HK
• Employees: 55
• Sector: Financial
• Sector Strength: 87
• Industry: Financial - Credit Services
• EPS (TTM): -0.06
• Shares Outstanding: 546,529,540
• 10 Day Avg. Volume: 151,573
• 30 Day Avg. Volume: 373,968
• PEG Ratio: <0.01
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.94K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Zhong Ji Longevity Science Group Limited has a moderate overall stock score of 55. The financial performance reflects growth but also volatility and cash flow challenges. Technical analysis shows positive momentum, yet the valuation metrics highlight concerns with a negative P/E ratio and lack of dividends. Despite some strengths, the company's financial stability and growth prospects remain uncertain.

Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model

Company Description

Zhong Ji Longevity Science Group Limited (0767) is a company focused on advancing the science of longevity and enhancing quality of life through its innovative products and services. Operating within the health and wellness sector, the company specializes in developing and providing solutions aimed at promoting longevity and well-being, leveraging scientific research and technological advancements.

How the Company Makes Money

Zhong Ji Longevity Science Group Limited generates revenue through the sale of its health and wellness products and services. The company's key revenue streams include direct sales of longevity-related products, subscription-based wellness programs, and potential collaborations with healthcare institutions for research and development. Partnerships with scientific communities and technology firms may also contribute to its earnings by facilitating product innovation and expanding market reach.

Zhong Ji Longevity Science Group Limited Financial Statement Overview

Summary

Zhong Ji Longevity Science Group Limited shows a mixed financial picture. The income statement reflects growth but also highlights significant volatility and profitability challenges. The balance sheet is strong with no current debt, but overall asset and equity levels have been declining. Cash flow issues, particularly with operating and free cash flow, pose a concern for sustainable operations. Overall, while there are strengths, the company faces financial stability and growth challenges moving forward.

Income Statement

The company's income statement shows moderate performance with significant volatility. The gross profit margin is high due to zero cost of goods sold, but the net profit margin is negative, reflecting high expenses relative to revenue. Revenue growth is strong over the last year, but historical data shows inconsistency in revenue and profitability.

Balance Sheet

The balance sheet is relatively strong with no debt in the latest year, resulting in a favorable debt-to-equity ratio. High equity ratio indicates stability, but declining stockholders' equity and total assets over recent years highlight potential risks.

Cash Flow

Cash flow analysis reveals challenges with operating cash flow consistently underperforming relative to net income. Free cash flow growth is non-existent due to zero free cash flow in the latest year, which indicates potential cash management issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
168.63M	64.99M	89.44M	62.98M	81.41M
	Gross Profit
57.41M	56.28M	79.41M	49.40M	71.83M
	EBIT
85.89M	-15.49M	708.00K	-9.72M	-13.90M
	EBITDA
-29.96M	13.02M	4.92M	16.13M	-6.74M
	Net Income Common Stockholders
-34.73M	2.31M	-904.00K	6.05M	-11.49M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
47.84M	81.08M	60.07M	19.44M	40.80M
	Total Assets
525.63M	509.25M	484.84M	517.50M	478.24M
	Total Debt
0.00	20.20M	11.76M	12.93M	8.70M
	Net Debt
-47.84M	-60.88M	-48.31M	-6.51M	-32.09M
	Total Liabilities
125.49M	78.79M	63.99M	46.78M	23.35M
	Stockholders Equity
373.42M	403.40M	393.83M	443.75M	428.83M
Cash Flow		Free Cash Flow
0.00	15.28M	11.08M	-40.51M	-192.89M
	Operating Cash Flow
0.00	15.28M	12.11M	-39.62M	-191.54M
	Investing Cash Flow
0.00	382.00K	16.44M	2.91M	70.11M
	Financing Cash Flow
0.00	6.02M	-7.45M	3.44M	-1.43M

Zhong Ji Longevity Science Group Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.37
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0767, the sentiment is Neutral. The current price of 0.37 is below the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.38, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.82 is Neutral, neither overbought nor oversold. The STOCH value of 20.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0767.

Zhong Ji Longevity Science Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1123	74 Outperform	HK$141.05M	17.10	1.19%	8.47%	-5.52%	-85.74%
3839	66 Neutral	$514.26M	3.70	7.60%	―	76.15%	334.56%
1177	66 Neutral	$72.47B	38.17	6.14%	1.55%	7.63%	-24.23%
Sector *	64 Neutral	$12.82B	9.87	7.67%	17000.34%	12.39%	-5.85%
1518	59 Neutral	HK$585.72M	11.29	8.82%	3.15%	-10.82%	-43.85%
0767	55 Neutral	HK$202.22M	―	-8.94%	―	156.72%	-2758.33%
0923	36 Underperform	HK$72.35M	―	-8.94%	―	7.90%	-44.09%

Zhong Ji Longevity Science Group Limited Corporate Events

Zhong Ji Longevity Science Group Announces Annual General Meeting

Zhong Ji Longevity Science Group Limited has announced its upcoming annual general meeting scheduled for June 27, 2025, in Hong Kong. The meeting will address several key resolutions including the re-election of directors, re-appointment of auditors, and authorization for the board to manage share allotments. This meeting is significant as it will influence the company’s governance and financial strategies, impacting stakeholders and potentially affecting the company’s market positioning.

Zhong Ji Longevity Science Group Acquitted but Faces Financial Setbacks

Zhong Ji Longevity Science Group Limited faced a legal challenge when the Department of Health, through the Office for Regulation of Private Healthcare Facilities, canceled its Day Procedure Centre License due to allegations of using unlicensed equipment and handling unregistered pharmaceutical products. Despite being acquitted of these allegations, the company suffered reputational damage and financial losses, as it had to vacate its premises and write off significant capital investments.

Zhong Ji Longevity Science Group Forms Joint Venture with Hua Li Life in China

Zhong Ji Longevity Science Group Limited has announced the formation of a joint venture with Hua Li Life Sciences Technology Company Limited in China. The joint venture, owned 51% by Zhong Ji Health and 49% by Hua Li Life, will focus on providing longevity health services in China, with an initial registered capital of RMB1,000,000. This collaboration aims to leverage Hua Li Life’s expertise in life sciences and conference organization to enhance Zhong Ji’s market presence in the promising health longevity science sector, catering to the increasing demand from wealthy clients for health and immunity improvement solutions.

Zhong Ji Longevity Reports Revenue Surge but Posts Net Loss for 2024

Zhong Ji Longevity Science Group Limited announced its annual results for the year ended 31 December 2024, reporting a significant revenue increase of approximately 155.4% to HK$166.2 million compared to the previous year. Despite the revenue growth, the company experienced a net loss after tax of approximately HK$34.8 million, a decline from the net profit of HK$2.5 million in 2023, and decided not to recommend a final dividend for the year.

Zhong Ji Longevity Science Group Issues Profit Warning for FY24

Zhong Ji Longevity Science Group Limited has issued a profit warning for the fiscal year ending December 31, 2024, anticipating a net loss between HK$32 million and HK$35 million, a significant decline from the previous year’s profit. This downturn is attributed to one-off legal and service fees related to loan recovery, substantial marketing costs for MNM supplements, and restructuring costs associated with the removal of the retail sales division and enhancement of service and product lines.

Zhong Ji Longevity Science Group Schedules Board Meeting for Annual Results

Zhong Ji Longevity Science Group Limited has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the payment of a final dividend and address other business matters, potentially impacting the company’s financial strategies and shareholder returns.

Zhong Ji Longevity Science Group Forms Strategic Partnership with Super Fire Technology

Zhong Ji Longevity Science Group Limited has entered into a strategic cooperation framework agreement with Super Fire (Xiamen) Technology Co., Ltd., leveraging mutual strengths to explore new business areas and enhance their longevity science and AI applications. This collaboration is expected to expand the company’s market share and contribute to sustainable revenue growth through joint development efforts and strategic distribution of health products.